Child and adolescent schizophrenia: Pharmacological approaches

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2053-2068

  Madaan, Vishal ^a   Dvir, Yael ^b   Wilson, Daniel R ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotics; Childhood schizophrenia; Typical antipsychotics

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DROPERIDOL; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; METFORMIN; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ADOLESCENT; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CARDIOVASCULAR SYMPTOM; CATATONIA; CHILD; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DELUSION; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EEG ABNORMALITY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; EYE EXAMINATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HEMATOLOGIC DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPERTHERMIA; INSOMNIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MEDLINE; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE NECROSIS; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; NONALCOHOLIC FATTY LIVER; OBESITY; OPTIMAL DRUG DOSE; PARKINSONISM; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PULSE RATE; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TACHYCARDIA; TARDIVE DYSKINESIA; THYROXINE BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 50949110318     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2053     Document Type: Review

References (74)

1. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007;3(3):CD004027
2. Young CM, Findling RL. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother 2004;4(1):53-60
3. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2006;15(3):141-8
4. Schulz SC, Findling RL, Wise A, et al. Child and adolescent schizophrenia. Psychiatr Clin North Am 1998;21(1):43-56
5. Frazier JA, Alaghband-Rad J, Jacobsen L, et al. Pubertal development and onset of psychosis in childhood onset schizophrenia. Psychiatry Res 1997;70(1):1-7
6. American Academy of Child and Adolescent Psychiatry. AACAP official action. summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American academy of child and adolescent psychiatry. J Am Acad Child Adolesc Psychiatry 2000;39(12):1580-2
7. Asarnow JR, Tompson MC, McGrath EP. Annotation: Childhood-onset schizophrenia: Clinical and treatment issues. J Child Psychol Psychiatry 2004;45(2):180-94
8. Masi G, Mucci M, Pari C. Children with schizophrenia: Clinical picture and pharmacological treatment. CNS Drugs 2006;20(10):841-66
9. Ross RG, Heinlein S, Tregellas H. High rates of comorbidity are found in childhood-onset schizophrenia. Schizophr Res 2006;88(1-3):90-5
10. Rhinewine JP, Lencz T, Thaden EP, et al. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry 2005;58(9):705-12
11. Werry JS, McClellan JM, Andrews LK, Ham M. Clinical features and outcome of child and adolescent schizophrenia. Schizophr Bull 1994;20(4):619-30
12. Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002;41(5):538-45
13. Bettes BA, Walker E. Positive and negative symptoms in psychotic and other psychiatrically disturbed children. J Child Psychol Psychiatry 1987;28(4):555-68
14. McKenna K, Gordon CT, Lenane M, et al. Looking for childhood-onset schizophrenia: The first 71 cases sacened. J Am Acad Child Adolesc Psychiatry 1994;33(5):636-44
15. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60-71
16. Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992;28(2):183-6
17. Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976;19(1):99-104
18. Realmuto GM, Erickson WD, Yellin AM, et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984;141(3):440-2
19. Frazier JA, McClellan J, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders [TEOSS]: demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007;46(8):979-88
20. McClellan J, Sikich L, Findling RJ, et al. Treatment of early-onset schizophrenia spectrum disorders [TEOSS]: rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007;46(8):969-78
21. Greenhill LL, Solomon M, Pleak R, Ambrosini P. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 1985;46(8 Pt 2):20-5
22. Haas M, Unis AS, Copenhaver M, et al. Efficacy and safety of risperidone in adolescents with schizophrenia [poster]. Presented at 160th Annual Meeting of the American Psychiatric Association; 19-24 May 2007; San Diego, CA
23. Pandina G, Kushner S, Singer J, et al. Comparison of two risperidone dose ranges in adolescents with schizophrenia [poster]. Presented at the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiany, 23-28 October 2007; Boston, MA
24. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: An open pilot study. J Am Acad Child Adolesc Psychiatry 1997;36(5):694-700
25. Grcevich SJ, Findling RL, Rowane WA, et al. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6(4):251-7
26. Quintana H, Wilson MS 2nd, Purnell W, et al. An open-label study of olanzapine in children and adolescents with schizophrenia. J Psychiatr Pract 2007;13(2):86-96
27. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63(7)-721-30
28. Mozes T, Ebert T, Michal SE, et al. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2006;16(4):393-403
29. Mozes T, Greenberg Y, Spivak B, et al. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003;13(3):311-7
30. Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003;13(3):301-9
31. Sholevar EH, Baron DA, Hardie TL, Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000;10(2):69-78
32. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol 1998;8(2):107-13
33. Finding R, Robb A, Nyilas M, et al. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia [poster] Presented at 160th Annual Meeting of the American Psychiatric Association; 19-24 May 2007; San Diego, CA
34. Schimmelmann BG, et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007;17(6):768-78
35. McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003;13(1):75-82
36. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001;11(4):415-24
37. Patel N, Sierk P, Dorson P, Crismon M. Experience with Ziprasidone. J Am Acad Child Adolesc Psychiatry 2002;41(5):495
38. Sallee FR, Gilbert DL, Vinks AA, et al. Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry 2003;42(8):902-7
39. Kranzler HN, Kester HM, Gerbino-Rosen G, et al. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 2006;15(1):135-59
40. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63(5):524-9
41. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37(4):377-85
42. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007;46(10):1349-56
43. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53(12):1090-7
44. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2005;44(1):55-63
45. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolcsc Psychiatry 2006;45(7):771-91
46. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41(3):337-43
47. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology [Berl] 2004;174(4):477-89
48. Wu RR, Zhao JP. Metformin addition attenuates olanzapine induced weight gam in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165(3):352-8
49. Wu RR, Zhao JP. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299(2):185-93
50. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14(3):350-8
51. Correll CU, Harris JL, Pantaleon Moya RA, et al. Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr Res 2007;92[1-3]:103-7
52. Courvoisie HE, Cooke DW, Riddle MA. Olanzapine-induced diabetes in a seven-year-old boy. J Child Adolesc Psychopharmacol 2004;14(4):612-6
53. Beliard S, Valero R, Vialettes B. Atypical neuroleptics and diabetes. Diabetes Metab 2003;29(3):296-9
54. Saito E, Kafantaris V. Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 2002;12(3):231-6
55. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001;138(6):936-8
56. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66(Suppl 7):29-40
57. Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005;44(1):73-9
58. Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003;42(6):642-50
59. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67(4):575-83
60. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40(10):1113-7
61. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998;43(6):596-604
62. Seeman P, Bzowej NH, Guan HC, et al. Hurnan brain dopamine receptors in children and aging adults. Synapse 1987;1(5):399-404
63. Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37(2):221-7
64. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15(1):177-206
65. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161(3):414-25
66. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007;17(5):647-56
67. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007;30(1):47-51
68. Silva RR, Munoz DM, Alpert M, et al. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(2):187-94
69. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15(5):365-71
70. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the united states. N Engl J Med 1993;329(3):162-7
71. Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44(10):1024-31
72. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13(3):401-4
73. Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002;159(1):109-15
74. Kumra S, Herion D, Jacobsen LK, et al. Case study: Risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36(5):701-5